Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications

Current Diabetes Reports

Volumn 5, Issue 2, 2005, Pages 91-97

  Xu, Yizhen ^b   He, Zhiheng ^b   King, George L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; BENFOTIAMINE; GLITAZONE DERIVATIVE; HEXOSAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC OXIDE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; THIOCTIC ACID; UNCLASSIFIED DRUG;

ATHEROGENESIS; CARBOHYDRATE ABSORPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; DISEASE MODEL; DYSLIPIDEMIA; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INNATE IMMUNITY; KIDNEY DISEASE; NEUROPATHY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; RISK FACTOR; RNA TRANSLATION; VITAMIN SUPPLEMENTATION;

EID: 20444479826     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0034-z     Document Type: Review

References (83)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-853.
3. Nathan DM, Lachin J, Cleary P, et al.: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348:2294-2303.
4. Renard CB, Kramer F, Johansson F, et al.: Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004, 114:659-668.
5. Park L, Raman KG, Lee KJ, et al.: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998, 4:1025-1031.
6. Goldberg RB, Capuzzi D: Lipid disorders in type 1 and type 2 diabetes. Clin Lab Med 2001, 21:147-72, vii.
7. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
8. Krolewski AS, Kosinski EJ, Warram JH, et al.: Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987, 59:750-755.
9. Garg A: Management of dyslipidemia in IDDM patients. Diabetes Care 1994, 17:224-234.
10. Larsson LI, Alm A, Lithner F, et al.: The association of hyperlipidemia with retinopathy in diabetic patients aged 15-50 years in the county of Umea. Acta Ophthalmol Scand 1999, 77:585-591.
11. Jenkins AJ, Lyons TJ, Zheng D, et al.: Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003, 64:817-828.
12. Tarnow L, Rossing P, Nielsen FS, et al.: Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy. Diabetes Care 1996, 19:1382-1387.
13. Kozek E, Gorska A, Fross K, et al.: Chronic complications and risk factors in patients with type 1 diabetes mellitus - retrospective analysis [in Polish]. Przegl Lek 2003, 60:773-777.
14. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
15. He Z, Rask-Madesen C, King GL: Pathogenesis of diabetic microvascular complications. In International Textbook of Diabetes Mellitus, edn 3, vol 2. Edited by De Fronzo R, et al. John Wiley & Sons; 2004:1135-1159.
16. He Z, King GL: Microvascular complications of diabetes. Endocrinol Metab Clin North Am 2004, 33:215-xii.
17. Rask-Madsen C, He Z, King GL: Mechanisms of diabetic microvascular complications. In Joslin's Diabetes Mellitus. Edited by Kahn RC, et al. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:823-837.
18. Yegin A, Ozben T, Yegin H: Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 1995, 25:157-161.
19. Numano F, Tanaka A, Makita T, et al.: Glycated lipoprotein and atherosclerosis. Ann N Y Acad Sci 1997, 811:100-113.
20. Shen GX: Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. Mol Cell Biochem 2003, 246:69-74.
21. Januszewski AS, Alderson NL, Metz TO, et al.: Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 2003, 31:1413-1416.
22. Yan SF, Ramasamy R, Naka Y, et al.: Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
23. Bucala R, Makita Z, Vega G, et al.: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994, 91:9441-9445.
24. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
25. Soulis-Liparota T, Cooper M, Papazoglou D, et al.: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991, 40:1328-1334.
26. Hammes HP, Martin S, Federlin K, et al.: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991, 88:11555-11558.
27. Cooper ME: Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 2004, 17:31S-38S.
28. Goova MT, Li J, Kislinger T, et al.: Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001, 159:513-525.
29. Wendt TM, Tanji N, Guo J, et al.: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
30. Kuroki T, Isshiki K, King GL: Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. J Am Soc Nephrol 2003, 14:S216-S220.
31. Lee IK, Kim HS, Bae JH: Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia. Int J Clin Pract Suppl 2002, 129:59-64.
32. Maytin M, Leopold J, Loscalzo J: Oxidant stress in the vasculature. Curr Atheroscler Rep 1999, 1:156-164.
33. Erciyas F, Taneli F, Arslan B, et al.: Glycemic control, oxidative stress, and lipid profile in children with type 1 diabetes mellitus. Arch Med Res 2004, 35:134-140.
34. Flores L, Rodela S, Abian J, et al.: F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism 2004, 53:1118-1120.
35. Zhang Z, Apse K, Pang J, Stanton RC: High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 2000, 275:40042-40047.
36. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19:257-267.
37. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
38. Yusuf S, Dagenais G, Pogue J, et al.: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154-160.
39. Lonn E, Yusuf S, Hoogwerf B, et al.: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002, 25:1919-1927.
40. Rask-Madsen C, King GL: Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005, Jan 6; [Epub ahead of print].
41. Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001, 18:945-959.
42. Way KJ, Chou E, King GL: Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 2000, 21:181-187.
43. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002, 288:2579-2588.
44. Aiello LP, Bursell SE, Clermont A, et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
45. Koya D, Haneda M, Kikkawa R, et al.: d-alpha-tocopherol treatment prevents glomerular dysfunctions in diabetic rats through inhibition of protein kinase C-diacylglycerol pathway. Biofactors 1998, 7:69-76.
46. Koya D, Haneda M, Nakagawa H, et al.: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14:439-447.
47. Kim H, Sasaki T, Maeda K, et al.: Protein kinase C-beta selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes 2003, 52:2102-2109.
48. Nakamura J, Kato K, Hamada Y, et al.: A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999, 48:2090-2095.
49. Marshall S, Bacote V, Traxinger RR: Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1991, 266:4706-4712.
50. Hawkins M, Barzilai N, Liu R, et al.: Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 1997, 99:2173-2182.
51. Daniels MC, Ciaraldi TP, Nikoulina S, et al.: Glutamine:fructose-6-phosphate amidotransferase activity in cultured human skeletal muscle cells: relationship to glucose disposal rate in control and non-insulin-dependent diabetes mellitus subjects and regulation by glucose and insulin. J Clin Invest 1996, 97:1235-1241.
52. Buse MG, Robinson KA, Gettys TW, et al.: Increased activity of the hexosamine synthesis pathway in muscles of insulin-resistant ob/ob mice. Am J Physiol 1997, 272:E1080-E1088.
53. Yki-Jarvinen H, Daniels MC, Virkamaki A, et al.: Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 1996, 45:302-307.
54. Akimoto Y, Kreppel LK, Hirano H, et al.: Increased O-GlcNAc transferase in pancreas of rats with streptozotocin-induced diabetes. Diabetologia 2000, 43:1239-1247.
55. Nerlich AG, Sauer U, Kolm-Litty V, et al.: Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes 1998, 47:170-178.
56. James LR, Tang D, Ingram A, et al.: Flux through the hexosamine pathway is a determinant of nuclear factor kappaB-dependent promoter activation. Diabetes 2002, 51:1146-1156.
57. Kolm-Litty V, Sauer U, Nerlich A, et al.: High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 1998, 101:160-169.
58. Burt DJ, Gruden G, Thomas SM, et al.: P38 mitogen-activated protein kinase mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells. Diabetologia 2003, 46:531-537.
59. Du XL, Edelstein D, Dimmeler S, et al.: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001, 108:1341-1348.
60. Federici M, Menghini R, Mauriello A, et al.: Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002, 106:466-472.
61. Hammes HP, Du X, Edelstein D, et al.: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
62. Dandona P: Endothelium, inflammation, and diabetes. Curr Diab Rep 2002, 2:311-315.
63. Schram MT, Chaturvedi N, Schalkwijk C, et al.: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003, 26:2165-2173.
64. Ben Mahmud BM, Mann GE, Datti A, et al.: Tumor necrosis factor-alpha in diabetic plasma increases the activity of core 2 GlcNAc-T and adherence of human leukocytes to retinal endothelial cells: significance of core 2 GlcNAc-T in diabetic retinopathy. Diabetes 2004, 53:2968-2976.
65. Doganay S, Evereklioglu C, Er H, et al.: Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 2002, 16:163-170.
66. Limb GA, Chignell AH, Green W, et al.: Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 1996, 80:168-173.
67. Limb GA, Soomro H, Janikoun S, et al.: Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin Exp Immunol 1999, 115:409-414.
68. Cybulsky MI, Gimbrone MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
69. Jager A, van Hinsbergh VW, Kostense PJ, et al.: Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000, 49:485-491.
70. Dardik F, Varon D, Tamarin I, et al.: Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000, 83:338-344.
71. Cosentino F, Eto M, De Paolis P, et al.: High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003, 107:1017-1023.
72. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
73. Kislinger T, Fu C, Huber B, et al.: N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999, 274:31740-31749.
74. Hofmann MA, Drury S, Hudson BI, et al.: RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002, 3:123-135.
75. Yan SS, Wu ZY, Zhang HP, et al.: Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003, 9:287-293.
76. Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 2000, 343:338-344.
77. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41:1241-1248.
78. Pickup JC, Mattock MB: Activation of the innate immune system as a predictor of cardiovascular mortality in type 2 diabetes mellitus. Diabet Med 2003, 20:723-726.
79. Mather K, Anderson TJ, Verma S: Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res 2001, 38:415-422.
80. Kuboki K, Jiang ZY, Takahara N, et al.: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000, 101:676-681.
81. Montagnani M, Chen H, Barr VA, et al.: Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001, 276:30392-30398.
82. Federici M, Pandolfi A, De Filippis EA, et al.: G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 2004, 109:399-405.
83. Vicent D, Ilany J, Kondo T, et al.: The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 2003, 111::1373-1380.